Dual antithrombotic therapy in PCI: Potential harm in routine adoption.
Partha SardarJinnette Dawn AbbottPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019)
Randomized clinical trials support the use of dual antithrombotic therapy (DAT) in PCI patients but outcomes in clinical practice are unclear. In this observational study of patients at high risk for thromboembolism and bleeding, routine use of a P2Y12 inhibitor alone compared with DAPT with OAC was associated with a significantly higher risk of ischemic events without a lower risk of bleeding. Future randomized trials and observational analyses of large registries are needed to select the ideal patient population for DAT.
Keyphrases
- atrial fibrillation
- clinical practice
- antiplatelet therapy
- coronary artery disease
- percutaneous coronary intervention
- end stage renal disease
- acute coronary syndrome
- acute myocardial infarction
- newly diagnosed
- ejection fraction
- chronic kidney disease
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- heart failure
- case report
- stem cells
- patient reported outcomes
- adipose tissue
- coronary artery bypass grafting
- left ventricular
- risk assessment
- mesenchymal stem cells
- subarachnoid hemorrhage
- oxidative stress
- human health
- blood brain barrier
- insulin resistance
- replacement therapy